Markers of Oxidative Stress in Inflammatory Bowel Diseases: Risk Factors and Implications for a Dietetic Approach

Condition(s) studied

Investigational drug(s) / intervention(s)

Antioxidant diet: The "antioxidant diet" will include the principal antioxidant molecules/nutrients previously shown to be beneficial in IBD: Flavonoids, particularly resveratrol and curcumin; Olive oil; Glutathione, Vitamins A, C, E; Carotenoids; Selenium and Omega 3 Fatty Acids (PUFAs). The daily amount of these substances will be calculated following the published evidence, whether these amounts will not be achievable by a standard diet, a supplementary formulation will be proposed.

Normal dietetic scheme: Isocaloric, normolipidic diet for age and sex

Study summary

Inflammatory bowel disease (IBD), including Crohn's disease (CD), Ulcerative Colitis (UC) and IBD-unclassified (IBD-U) is a chronic inflammatory intestinal disorders that affect both children and adults. Patients with IBD can present with severe gastrointestinal symptoms, require frequent hospitalizations, expensive medical treatments and can develop invalidating complications requiring surgery. The incidence of IBD is increasing worldwide. The pathogenesis is multifactorial with immunological, environmental and genetic factors contributing to the disease. There is evidence that oxidative stress (OS) imbalance is involved in IBD onset and evolution, although the exact contribution to the pathogenes is unclear. An antioxidant dietetic approach is promising as an adjunctive treatment of IBD. The main aims of this project are to characterize the OS imbalance in IBD in relation to disease's features and to genetic factors and to evaluate the efficacy of an antioxidant dietetic treatment

Eligibility

Primary outcome measure(s)

• Blood levels of ROS and glutathione in patients with IBD and controls — Baseline
  Blood levels of ROS will be determined by cytofluorimetry, blood levels of glutathione by spectrofluorimetry
• Total antioxidant capacity (Trolox equivalent and ferrous equivalent) in patients with IBD and controls — Baseline
  Trolox equivalent will be assessed by antioxidant assay Kit, ferrous equivalent instead wille require a manual assessment.
• Antioxidant enzymes pattern (GST, SOD, GPxs, GR enzyme levels, activity and transcripts) in patients with IBD and controls — Baseline
  Spectrophotometer will be used to assess enzyme levels and activity, cDNA kit to determine enzyme transcripts.
• Plasma hydroperoxides and thiobarbituric acid reactive species in patients with IBD and controls — Baseline
  Plasma hydroperoxides will be detected by LPO ELISA kit, thiobarbituric acid reactive species by TBARS assay kit.
• Urine oxidized guanines (8-OHdG, 8-OHG e guanosine) levels in patients with IBD and controls — Baseline
  DNA/RNA oxydate damage kit will be used to study urine oxidized guanines levels.

Trial sites (2)

More Università Politecnica delle Marche trials in Italy

Other trials for the same condition